Study guide

5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

Advanced Oncology Certified Nurse Practitioner AOCNP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide

2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening

2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling

3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging

3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment

4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship

4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence

5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy

5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies

6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology

7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy

7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies

8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response

8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety

9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions

10 Chapter 10: Supportive Care - Symptom & Comorbidity Management

10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management

11 Chapter 11: Oncologic Emergencies

11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH

12 Chapter 12: Psychosocial Issues

12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources

13 Chapter 13: Professional Practice & Roles of the APRN

13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education

5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

Key Takeaways Explain This Topic AI

Adherence to oral antineoplastic therapy commonly falls below 80% and both under-adherence and over-adherence cause harm, so adherence must be measured at every visit rather than assumed.

Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort can reduce plasma concentrations of many oral kinase inhibitors enough to cause treatment failure.

Proton pump inhibitors and H2 blockers substantially reduce absorption of pH-dependent agents such as erlotinib, dasatinib, and pazopanib, so acid suppression must be reviewed before starting these drugs.

Food effects differ by agent: abiraterone must be taken on an empty stomach because food dramatically increases exposure, while capecitabine is taken within 30 minutes after a meal.

Oral antineoplastics are hazardous drugs under USP <800>, so patients and caregivers require instruction on handling, storage, spill management, and disposal at home.

Last updated: August 2026

5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring

Blueprint focus: ONCC Domain II.B — systemic therapy. Oral agents are systemic therapy delivered without a nurse present. That single fact changes everything about safety, and the exam tests it through adherence, drug interaction, food effect, and home-handling stems.

Why Oral Therapy Is Not Simply More Convenient

An infusion is witnessed, dose-verified, and administered by a nurse who can stop it. An oral kinase inhibitor is taken by a patient who may forget doses, double up after missing one, take it with grapefruit juice, add an over-the-counter omeprazole, or stop it entirely because of a rash they were too embarrassed to report. Every safeguard that the infusion suite provides has to be rebuilt through education, monitoring, and follow-up.

Adherence

Adherence to oral anticancer therapy is frequently reported below 80%, and it declines as therapy lengthens. Both directions are dangerous.

Under-adherence causes subtherapeutic exposure and treatment failure. In chronic myeloid leukemia, adherence below 90% is associated with markedly lower rates of major molecular response — one of the clearest dose-response relationships in oncology.

Over-adherence — taking a missed dose late, doubling up, or continuing through a toxicity that should have triggered a hold — causes avoidable grade 3 and 4 events.

Root causes and matched interventions

Barrier What it looks like Intervention

Financial toxicity Delayed refills, pill splitting, "I'm stretching it out" Financial navigator, manufacturer patient assistance program, copay foundation grant, specialty pharmacy benefits check before the first fill

Unmanaged toxicity Silent self-discontinuation after diarrhea or rash Proactive prophylaxis, scheduled early check-in calls, explicit permission to call

Complexity Multiple agents, cycled on-off schedules, food restrictions Written calendar, pill organizer, alarms, simplified regimen where possible

Cognitive or sensory limits Missed doses, confusion about the schedule Caregiver involvement, large-print instructions, teach-back at every visit

Beliefs "I feel fine so I stopped," or fear of dependence Explain the mechanism and what happens if levels drop

Asymptomatic disease Adjuvant endocrine therapy abandoned in year 2 Frame absolute benefit; treat side effects rather than accepting discontinuation

Measure adherence, do not ask a yes-or-no question. Use a normalizing, open prompt — "Most people miss doses sometimes. In the last week, how many did you miss?" — plus pill counts, refill records from the specialty pharmacy, and where available a validated instrument.

  • Drug and Food Interactions That Change Outcomes
  • CYP3A4

Most oral kinase inhibitors are CYP3A4 substrates.

Strong inducers — rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's wort , enzalutamide — lower drug concentrations enough to cause treatment failure . Induction takes days to develop and days to reverse after stopping.

Strong inhibitors — ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir, and grapefruit and Seville orange juice — raise concentrations and cause toxicity .

Whenever a strong interacting drug is unavoidable, either the antineoplastic dose is adjusted according to labeling or a non-interacting alternative is substituted. Antifungal prophylaxis is a common real-world trigger for this problem.

Gastric pH

Several oral agents require an acidic stomach to dissolve. Proton pump inhibitors and H2 receptor antagonists can lower exposure substantially and cause failure.

Markedly affected: erlotinib, dasatinib, pazopanib, nilotinib, gefitinib, capecitabine (with PPI, an association with worse outcomes has been reported).

Mitigation: avoid PPIs where possible; if an H2 blocker is required, separate dosing by the interval specified in the label; antacids can often be separated by a few hours.

Food

Agent Requirement Reason

Abiraterone acetate Empty stomach — 1 hour before or 2 hours after food Food can raise exposure severalfold, causing toxicity

  • Capecitabine Within 30 minutes after a meal Labeling and trial dosing were established with food
  • Erlotinib 1 hour before or 2 hours after food Food increases bioavailability substantially
  • Nilotinib Avoid food 2 hours before and 1 hour after Food raises exposure and QT risk
  • Lapatinib Empty stomach Food markedly raises exposure
  • All CYP3A4 substrates Avoid grapefruit and Seville orange Irreversible intestinal CYP3A4 inhibition
  • QT prolongation

Nilotinib, vandetanib, and several other oral agents prolong the QT interval. Obtain a baseline electrocardiogram, correct potassium and magnesium, and review the full medication list for additive QT-prolonging drugs including ondansetron, methadone, azoles, and fluoroquinolones.

Safe Handling at Home

Oral antineoplastics remain hazardous drugs under USP <800> even outside the pharmacy. Teach patients and caregivers:

Do not crush, split, chew, or open capsules unless the label explicitly permits it.

Anyone other than the patient handling the tablets should wear disposable gloves .

Wash hands before and after every dose.

Store in the original labeled container, out of reach of children and pets, away from heat and humidity; do not put tablets in a shared weekly pill organizer unless a pharmacist confirms it is acceptable.

People who are pregnant or breastfeeding should not handle the drug.

Do not flush unused drug or put it in household trash — return it to a take-back program or the dispensing pharmacy.

For a spill, use gloves, contain and clean with disposable materials, and dispose of them in a sealed bag.

Body fluids may contain drug for several days after a dose; teach closing the toilet lid and flushing twice, and washing soiled linens separately.

Monitoring Cadence

Build the schedule around the specific agent's toxicity signature. A representative structure:

Before the first dose: confirm indication and biomarker, reconcile all medications and supplements, check baseline organ function and electrocardiogram if indicated, verify insurance and out-of-pocket cost, and provide written and teach-back education.

Days 7 to 14: telephone check-in for tolerability and early toxicity — this is when most patients silently stop.

Every 2 to 4 weeks initially: targeted laboratory studies and toxicity grading (blood pressure and urine protein for VEGF inhibitors; thyroid function for several multikinase inhibitors; liver enzymes for many; complete blood count for PARP inhibitors; glucose and lipids for PI3K and mTOR inhibitors).

Ongoing: adherence measurement at every visit, re-reconciliation of medications at every visit, and dose modification per label rather than patient-initiated interruption.

Toxicity is a reason to hold and dose-reduce, not a reason for the patient to quit. Say that sentence out loud to every patient starting an oral agent.

Loading diagram... Oral Antineoplastic Safety Workflow